E-resources
-
Machado, Marina; Valerio, Maricela; Álvarez‐Uría, Ana; Olmedo, María; Veintimilla, Cristina; Padilla, Belén; De la Villa, Sofía; Guinea, Jesús; Escribano, Pilar; Ruiz‐Serrano, María Jesús; Reigadas, Elena; Alonso, Roberto; Guerrero, José Eugenio; Hortal, Javier; Bouza, Emilio; Muñoz, Patricia; Alcalá, Luis; Aldámiz, Teresa; Álvarez, Beatriz; Arias, Alexi; Arroyo, Luis Antonio; Bermúdez, Elena; Burillo, Almudena; Candela, Ana; Carrillo, Raquel; Catalán, Pilar; Cercenado, Emilia; Cobos, Alejandro; Díez, Cristina; Estévez, Agustín; Fanciulli, Chiara; Galar, Alicia; García, Mª Dolores; Viedma, Darío García; Gijón, Paloma; González, Adolfo; Guillén, Helmuth; Haces, Laura Vanessa; Kestler, Martha; López, Juan Carlos; Losada, Carmen Narcisa; Marín, Mercedes; Martín, Pablo; Montilla, Pedro; Moure, Zaira; Palomo, María; Parras, Francisco; Pérez‐Granda, María Jesús; Pérez, Laura; Pérez, Leire; Pescador, Paula; Rincón, Cristina; Rodríguez, Belén; Rodríguez, Sara; Rojas, Adriana; Sánchez, Carlos; Sánchez, Mar; Serrano, Julia; Tejerina, Francisco; Vesperinas, Lara; Vicente, Teresa
Mycoses, February 2021, Volume: 64, Issue: 2Journal Article
Objectives Information on the recently COVID‐19‐associated pulmonary aspergillosis (CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU patients with coronavirus disease 2019 (COVID‐19), and review the published literature from Western countries. Methods Prospective study (March to May, 2020) that included all COVID‐19 patients admitted to a tertiary hospital. Modified AspICU and European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria were used. Results COVID‐19‐associated pulmonary aspergillosis was diagnosed in eight patients (3.3% of 239 ICU patients), mostly affected non‐immunocompromised patients (75%) with severe acute respiratory distress syndrome (ARDS) receiving corticosteroids. Diagnosis was established after a median of 15 days under mechanical ventilation. Bronchoalveolar lavage was performed in two patients with positive Aspergillus fumigatus cultures and galactomannan (GM) index. Serum GM was positive in 4/8 (50%). Thoracic CT scan findings fulfilled EORTC/MSG criteria in one case. Isavuconazole was used in 4/8 cases. CAPA‐related mortality was 100% (8/8). Compared with colonised patients, CAPA subjects were administered tocilizumab more often (100% vs. 40%, p = .04), underwent longer courses of antibacterial therapy (13 vs. 5 days, p = .008), and had a higher all‐cause mortality (100% vs. 40%, p = .04). We reviewed 96 similar cases from recent publications: 59 probable CAPA (also putative according modified AspICU), 56 putative cases and 13 colonisations according AspICU algorithm; according EORTC/MSG six proven and two probable. Overall, mortality in the reviewed series was 56.3%. Conclusions COVID‐19‐associated pulmonary aspergillosis must be considered a serious and potentially life‐threatening complication in patients with severe COVID‐19 receiving immunosuppressive treatment.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.